Acurx Pharmaceuticals Secures $7.1M in At-the-Market Offering

Event summary

  • Acurx Pharmaceuticals closed a registered direct offering of 825,085 shares at $3.03 per share, raising $2.5M upfront.
  • Concurrent private placement issued short-term warrants for up to 1,650,170 shares, potentially adding $4.6M in proceeds.
  • Proceeds will be used for working capital and general corporate purposes.
  • H.C. Wainwright & Co. acted as the exclusive placement agent.

The big picture

Acurx Pharmaceuticals' $7.1M at-the-market offering reflects the ongoing need for late-stage biopharmaceutical companies to secure non-dilutive financing to support clinical trials. The move comes amid increasing pressure to develop new antibiotics for difficult-to-treat bacterial infections, a critical area of unmet medical need. The strategic use of proceeds for working capital underscores the company's focus on sustaining operations while advancing its pipeline.

What we're watching

Execution Risk
Whether Acurx can advance its Phase 3-ready ibezapolstat for C. difficile Infection with the new funding.
Market Dynamics
How the $7.1M raise positions Acurx against competitors in the antibiotic development space.
Financial Strategy
The pace at which the short-term warrants will be exercised, determining the full potential of the offering.